Dr. William Oh, MD

• Medical Oncology

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana Farber Canc Institute

  Fellowship Hospital, 1997

• Brigham And Womens Hospital

  Residency Hospital, 1995

• Brigham And Womens Hospital

  Internship Hospital, 1993

• New York University

  Medical School, 1992

• English

• German

• Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer, 2019-07-01

• Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR, 2018-07-03

• Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease, 2014-02-12

• Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations Platinum-Based Chemotherapy for Advanced Prostate Cancer With DNA Repair Gene Aberrations, 2020-10-28

• A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab, 2018-09-18

• Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer, 2009-11-03

• TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression, 2013-10-15

• Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis, 2022-08-12

• Analysis of the Correlation between Endorectal MRI Response to Neoadjuvant Chemotherapy and Biochemical Recurrence in Patients with High-Risk Localized Prostate Cancer, 2013-05-28

• Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing, 2021-04-09

• Prostate Cancer in World Trade Center Responders Demonstrate Evidence of an Inflammatory Cascade, 2019-06-20

• Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors, 2014-07-15

• Multicenter Phase 2 Trial of the Hsp-90 Inhibitor, IPI-504 (retaspimycin hydrochloride), in Patients with Castration-Resistant Prostate Cancer, 2011-07-18

• Clinical trial awareness: Changes over time and sociodemographic disparities, 2015-02-10

• Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer, 2016-11-22

• Metabolic complications with the use of mTOR inhibitors for cancer therapy, 2013-05-16

• Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer, 2015-06-15

• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, 2022-12-06

• CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade, 2020-04-21

• Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition, 2016-05-10

• PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma, 2011-03-22

• Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality, 2009-04-14

• Small Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer, 2018-01-22

• Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis, 2013-07-13

• Analysis of the 10q11 Cancer Risk Locus ImplicatesMSMBandNCOA4in Human Prostate Tumorigenesis, 2010-11-11

• Phase II Study of Neoadjuvant Chemotherapy with Docetaxel and Bevacizumab in Patients with High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials Consortium Trial, 2012-01-26

• Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients, 2022-02-28

• Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis, 2012-12-08

• Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States, 2012-05-24

• GENOME-WIDE ASSOCIATION STUDY OF PROSTATE CANCER MORTALITY, 2010-10-26

• Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer, 2015-01-04

• Constructing Bayesian networks by integrating gene expression and copy number data identifiesNLGN4Yas a novel regulator of prostate cancer progression, 2016-09-10

• Risk factors for emergency room and hospital care among patients with solid tumors on immune checkpoint inhibitor therapy., 2021-03-01

• Disease-specific classification using deconvoluted whole blood gene expression, 2016-09-06

• Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting, 2017-08-10

• A robust blood gene expression-based prognostic model for castration-resistant prostate cancer, 2015-08-21

• EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer, 2018-08-29

• Inherited Variations inAR, ESR1, andESR2Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy, 2013-08-20

• Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer-Specific Mortality, 2011-03-02

• The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic, 2021-09-27

• Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer, 2010-09-13

• Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab, 2017-08-15

• Prostate Cancer Dormancy and Reactivation in Bone Marrow, 2021-06-16

• Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?, 2021-10-13

• Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report, 2009-08-19

• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma, 2016-12-20